Investigating the phase-solubility and compatibility study of anticancer drug complexed with β-cyclodextrin and HP–β-cyclodextrin | Zendy

Preeti Dhurve | Zendy; Atul Tripathi | Zendy; Bina Gidwani | Zendy; Amber Vyas | Zendy

Open Access

Investigating the phase-solubility and compatibility study of anticancer drug complexed with β-cyclodextrin and HP–β-cyclodextrin

Author(s) -

Preeti Dhurve,

Atul Tripathi,

Bina Gidwani,

Amber Vyas

Publication year - 2018

Publication title -

international journal of advances in pharmaceutical sciences

Language(s) - English

Resource type - Journals

ISSN - 0976-1055

DOI - 10.5138/09761055.1929

Subject(s) - solubility , cyclodextrin , differential scanning calorimetry , chemistry , dissolution , drug , gefitinib , nuclear chemistry , chromatography , combinatorial chemistry , organic chemistry , pharmacology , biochemistry , medicine , physics , receptor , epidermal growth factor receptor , thermodynamics

Poor aqueous solubility and dissolution rates are critical problems that hinders the formulation, development and delivery of most of BCS class II and class IV drugs. Gefitinib is a cytotoxic chemotherapeutic drug used in treatment of cancer. The objective of the present study was to investigate the drug-cyclodextrin compatibility study by FTIR and DSC study. The phase solubility study revealed formation of 1:1 stoichiometry binary inclusion complex. The complex was prepared by kneading method. FT-IR spectra provided the data indicating that the HP-β-CD was more effective than β-CD. Differential scanning calorimetry thermograms indicated stronger amorphization and entrapment of gefitinib with HP-β-CD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research